Skip to content

Clinical Value of Linear Ablation Without Pulmonary Vein Isolation in Persistent Atrial Fibrillation

Clinical Value of Linear Ablation Without Pulmonary Vein Isolation in Persistent Atrial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05468528
Acronym
CLEAR AF II
Enrollment
207
Registered
2022-07-21
Start date
2022-08-01
Completion date
2024-07-01
Last updated
2022-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Atrial Fibrillation, Persistent

Keywords

linear ablation

Brief summary

Based on previous theoretical foundation and clinical practice experience, the investigators further propose a multi-center randomized prospective trial to compare the pure linear ablation strategy without pulmonary vein isolation to traditional PVI ablation for persistent AF. population size is 207. The participants will be randomized to the linear ablation group and PVI ablation group with a 2:1 ratio. the follow-up period is 12 months. The primary outcome is freedom from atrial fibrillation, the secondary outcome is complications related to ablation.

Detailed description

Pulmonary vein isolation is recommended as the cornerstone of catheter ablation of atrial fibrillation by current guidelines, However, meta-analysis suggests that the success rate of continuous pulmonary vein isolation for persistent atrial fibrillation is only 43%. Therefore, in addition to pulmonary vein isolation, further research on substrate modification in the treatment of atrial fibrillation is particularly important. Based on our previous theoretical foundation and clinical practice experience, the investigators further propose a multi-center randomized prospective trial to compare the pure linear ablation strategy without pulmonary vein isolation to traditional PVI ablation for persistent AF. The linear ablation is performed on the basis of Ω-type linear ablation. Further stepwise ablation of the left atrial anterior wall increases the blockage of the LA roof and the MVA isthmus. Ablation in CS or ethanol ablation of vein of Marshall. Also, epicardial ablation on the roof or rigid between LAA-LPVs may be applied if necessary.

Interventions

PROCEDUREcatheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)

individualized stepwise linear ablation without pulmonary vein isolation

PROCEDUREcatheter radiofrequency ablation(PVI)

pulmonary vein isolation

Sponsors

First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
ZHONGNANSHAN MEDICAL FOUNDATION OF GUANGDONG PROVINCE
CollaboratorUNKNOWN
Beijing Hospital
CollaboratorOTHER_GOV
Wuhan Asia Heart Hospital
CollaboratorOTHER
Tianjin Medical University General Hospital
CollaboratorOTHER
Fuwai Yunnan Cardiovascular Hospital
CollaboratorOTHER
RenJi Hospital
CollaboratorOTHER
Chinese Academy of Medical Sciences, Fuwai Hospital
CollaboratorOTHER
China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patients suffering from persistent atrial fibrillation and referred to catheter ablation therapy. * patients agreeing to be enrolled, with the informed consent signed

Exclusion criteria

1. Sinus rhythm at the time of recruitment; 2. Age less than 18 years old or older than 75 years; 3. Transthoracic echocardiography suggests that the anteroposterior diameter of the left atrium is greater than 55 mm; 4. History of previous radiofrequency ablation of atrial fibrillation or surgical ablation History; 5. Left atrial thrombus recorded by ultrasound or CT; 6. Combined with severe lung disease; 7. Previous history of cardiac surgery; 8. Patients with hyperthyroidism, atrial septal defect, mitral stenosis, or severe coronary heart disease requiring further treatment

Design outcomes

Primary

MeasureTime frameDescription
Freedom from atrial fibrillation at 1 year12 months after the ablationRecurrent AF is defined as documented AF (through 12-lead ECG) episode lasting \>30 seconds after a 3-month blanking period.

Secondary

MeasureTime frameDescription
complications related to ablation12 months after the ablationTamponade, pericarditis and perforation following the ablation procedure

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026